Product Information:

MIBEGA 50mg Tablets contain Miglitol 50mg, an alpha-glucosidase inhibitor used in the management of type 2 diabetes mellitus. Miglitol works by competitively inhibiting alpha-glucosidase enzymes in the brush border of the small intestine, delaying the breakdown and absorption of complex carbohydrates and disaccharides. This action specifically reduces postprandial (after-meal) hyperglycemia without stimulating insulin secretion.

This intermediate-strength formulation is typically used after titration from the 25mg dose or in patients requiring stronger post-meal glucose control.

Uses of (MIBEGA 50MG TABLETS):

1. Monotherapy in adults with type 2 diabetes inadequately controlled by diet, exercise, or miglitol 25mg
2. Combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or insulin
3. Targeted management of postprandial blood glucose spikes

Key Benefits of (MIBEGA 50MG TABLETS):

1. Effective reduction of post-meal glucose excursions
2. Does not cause hypoglycemia when used as monotherapy
3. Weight-neutral—does not promote weight gain
4. May contribute to modest HbA1c reduction (0.5–1.0%)

How To Use (MIBEGA 50MG TABLETS):

1. Take three times daily, with the first bite of each main meal.
2. Swallow whole with water—do not crush or chew.
3. Only effective when taken with meals containing carbohydrates.
4. If a meal is skipped or is carbohydrate-free, skip the corresponding dose.

When Not to Use (MIBEGA 50MG TABLETS):

Do not use if you have:

1. Diabetic ketoacidosis
2. Chronic intestinal diseases (e.g., Crohn’s disease, ulcerative colitis, intestinal obstruction)
3. Conditions predisposing to intestinal obstruction (e.g., hernias, severe diverticulosis)
4. Malabsorption syndromes
5. Hypersensitivity to miglitol or any excipients

Side Effects of (MIBEGA 50MG TABLETS):

Common: Flatulence (gas), abdominal discomfort, diarrhea, bloating—due to fermentation of undigested carbs in the colon. These often diminish with continued use.

Rare: Skin rash, low serum iron levels.

Serious (rare):

1. Hypoglycemia (only when combined with insulin or sulfonylureas)—treat with glucose (dextrose), not sucrose (miglitol blocks sucrose digestion)

Dosage: (MIBEGA 50MG TABLETS):

1. Maintenance dose: 50mg three times daily with meals
2. May be increased to 100mg three times daily if needed and tolerated
3. Starting on 50mg: Only if previously titrated from 25mg
4. **Elderly or renal impairment (CrCl <25 mL/min)**: Avoid doses >50mg TDS

Who It’s For (MIBEGA 50MG TABLETS):

Adults with type 2 diabetes who have not achieved postprandial glucose targets on lower doses and can tolerate gastrointestinal side effects. Not suitable for patients with chronic digestive disorders.

Warnings & Precautions:

1. Gastrointestinal side effects are dose-dependent—start low and increase gradually
2. In hypoglycemia (when combined with other agents), use glucose tablets or gel—table sugar (sucrose) will not work
3. Avoid high-sucrose meals to minimize gas and bloating
4. Monitor HbA1c every 3 months to assess efficacy

Drug Interactions:

1. Digestive enzyme supplements (amylase, pancreatin): May reduce miglitol effectiveness
2. Intestinal adsorbents (e.g., activated charcoal): May decrease absorption
3. Sulfonylureas/insulin: ↑ Risk of hypoglycemia
4. Always inform your doctor about all medications and supplements.

Additional Information:

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children. Do not use after the expiration date. Available by prescription in Pakistan.